The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2023 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / The Antibody Society’s Committees / Communication & Membership Committee

Communication & Membership Committee

The Communications & Membership Committee engages in activities that promote the Society’s mission and encourages membership and sponsorship. In particular, we:

  • Develop initiatives to engage student, post-doctoral and early-career members
  • Assist with the continued development of the website, ensuring relevant and current content
  • Engage all members and the broader scientific community through various social media channels

Chair: Silvia Crescioli.  Co-chair: Alicia Chenoweth. Members: Jessica Anania, Sarra Idri, Vaishali Kapoor, Raquel Barroso Ferro, Janice Reichert and Jyothsna Visweswaraiah.

Dr. Jessica C. Anania is a postdoctoral researcher in the laboratory of Prof. E. Sally Ward and Prof Raimund Ober at the University of Southampton. She received her PhD, under the supervision of Prof. Mark Hogarth, characterizing a novel form of FcγRIIa in humans and non-human primates (Melbourne Australia). Her previous postdoctoral training examined the role of follicular dendritic cells in complement and IgG driven immune responses by novel image analysis techniques (Uppsala, Sweden). Jessica’s current work is focused on engineering antigen delivery vehicles to induce immunological tolerance.

 

Alicia Chenoweth, PhD, King’s College London

Dr. Alicia Chenoweth is a postdoctoral research associate in the Cancer Antibody Discovery and Immunotherapy group led by Prof. Sophia Karagiannis at King’s College London. Her work is focused on Fc engineering of antibodies for breast cancer therapy to better engage and influence the immune microenvironment. She received her PhD in Melbourne, Australia, under the supervision of Prof. Mark Hogarth, focusing on the interactions of human and non-human primate IgG antibodies with Fc receptors, and the impact of IgG Fc modification on immune cell function. Dr. Chenoweth was the co-chair of the Gordon Research Seminar for Antibody Biology and Engineering, held in 2022.

 

Silvia Crescioli, PhD, King’s College London

Dr. Silvia Crescioli is a senior post doc at King’s College London in Prof. Sophia Karagiannis’ Cancer Antibody Discovery & Immunotherapy Group, where she leads and supervises several projects focused on different areas of cancer immunology and immunotherapy, such as the study of B cells in cancer, antigen/antibody discovery, ADC development, and antibody production, engineering and glycoengineering. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence.

 

Vaishali Kapoor, PhD, Washington University in St. Louis

Dr. Vaishali Kapoor is an Assistant Professor in the Department of Radiation Oncology at the Washington University in St. Louis School of Medicine. Dr. Kapoor received her PhD in Cancer Biology from the All India Institute of Medical Sciences (New Delhi, India) and did her postdoctoral training at the Washington University School of Medicine. Her research involves development of novel drug candidates against radiation-inducible neo-antigens. Her lab is developing ways to target radiation sensitizers specifically to cancer with the goal of enhancing the efficacy of radiation therapy. Dr. Kapoor is also interested in understanding the mechanisms of resistance to standard-of-care cancer therapies. @ LinkedIn; Twitter; Washington University

 

Raquel Barroso Ferro, University of Aberdeen.

Raquel Barroso Ferro, student volunteer for the Education and Career Sub-Committee, is a first year PhD student at the University of Aberdeen, UK, currently working to develop a novel scFv-based immunotherapy against ovarian cancer. She previously completed an integrated Master’s in Biochemistry (MSci) from King’s College London and worked as a research assistant evaluating how various environmental chemicals can influence aspects of the human physiology. @ LinkedIn

 

Janice Reichert, PhD

Dr. Janice Reichert, Chief Operating Officer of The Antibody Society, is an internationally-recognized expert in the development of antibody therapeutics. She is Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. Dr. Reichert received her PhD in Chemistry from the University of Pennsylvania and did her post-doctoral training at Harvard Medical School.
Relevant links: Editor-in-chief, mAbs Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. mAbs 2023.

Dr. Jyothsna Visweswaraiah is a scientist with drug development experience in small biotech and a track record of advancing new therapies into the clinic. She currently heads the Antibody Discovery group in the Drug Creation department at Seismic Therapeutic. She was previously at FL75,  developing a modular, multi-specific biologics platform to address the complexities of biology with high resolution, and at Pandion Therapeutics where she developed novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Dr. Visweswaraiah has trained at Harvard Medical School and the National Institutes of Health. She has been an advocate for women in science and workplace inclusiveness. She mentors students interested in STEM careers, early career women scientists and serves on the Advisory Board of WEST, a non-profit organization supporting early to mid-career women. In recognition of her accomplishments, Dr. Visweswaraiah was nominated for the 2021 James S. Huston Antibody Science Talent Award.

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • FDA approves Zynyz™ (retifanlimab-dlwr) for Merkel cell carcinoma March 23, 2023
  • Ultralong CDR H3-based knobs: the smallest antibody fragment March 6, 2023
  • TRUST4 is now certified as AIRR-compliant March 1, 2023

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals